2. Signaling Pathways
  3. Neuronal Signaling
  4. Amyloid-β

Amyloid-β

β-amyloid peptide; Aβ; Abeta

Amyloid-β

Related Products

PDF 1.52 MB

Amyloid-β (Aβ) denotes peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease as the main component of theamyloid plaques found in the brains of Alzheimer patients. The peptides result from the amyloid precursor protein (APP), which is being cut by certain enzymes to yield Aβ. Amyloid-β molecules can aggregate to form flexible soluble oligomers which may exist in several forms. Amyloid-β peptide is due to overproduction of Aβ and/or the failure of clearance mechanisms. Amyloid-β self-aggregates into oligomers, which can be of various sizes, and forms diffuse and neuritic plaques in the parenchyma and blood vessels. Amyloid-β oligomers and plaques are potent synaptotoxins, block proteasome function, inhibit mitochondrial activity, alter intracellular Ca2+levels and stimulate inflammatory processes. Loss of the normal physiological functions of Aβ is also thought to contribute to neuronal dysfunction.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-175523
    MAO-B-IN-48
    		Inhibitor
    MAO-B-IN-48 is a selective MAO-B inhibitor (IC50 = 0.09 μM, Ki = 0.02 μM). MAO-B-IN-48 exhibits inhibitory activity against hBChE (IC50 = 1.10 μM, Ki = 0.43 μM) and AChE (IC50 = 0.56 μM, Ki = 0.14 μM). MAO-B-IN-48 suppresses self-induced aggregation of toxic β-amyloid peptides and exerts antioxidant activity, including DPPH radical scavenging, CUPRAC copper ion reduction, and superoxide anion scavenging. MAO-B-IN-48 can be used for the study of Alzheimer's disease (AD).
    MAO-B-IN-48
  • HY-P991534
    PF-04382923
    		Inhibitor
    PF-04382923 is a humanized IgG2Δa monoclonal antibody. PF-04382923 binds with high affinity to the free C-terminal regions of the amyloid-β peptides Aβ1-40 and Aβ1-42. PF-04382923 is indicated for the study of geographic atrophy (GA) associated with dry age-related macular degeneration (ARMD).
    PF-04382923
  • HY-149288
    hAChE/hBACE-1-IN-2
    		Inhibitor
    hAChE/hBACE-1-IN-2 is a potent, orally active, blood-brain barrier transboundary triple inhibitor of hAChE, hBChE, and HACE-1 with IC50s of 0.113 μM, 1.48 μM and 0.38 μM, respectively. hAChE/hBACE-1-IN-2 has antioxidant activity. hAChE/hBACE-1-IN-2 also inhibits Aβ11-42 aggregation. hAChE/hBACE-1-IN-2 can be used to study Alzheimer's disease.
    hAChE/hBACE-1-IN-2
  • HY-P0128F1
    FITC-β-Ala-β-Amyloid (25-35）
    FITC-β-Ala-β-Amyloid (25-35) is a fluorescent product labeled by FITC that can be used in Alzheimer's disease research.
    FITC-β-Ala-β-Amyloid (25-35）
  • HY-P1898
    β-Amyloid (13-27)
    β-Amyloid (13-27) is a peptide consisting of amino acid of 13 to 27 of beta amyloid protein.
    β-Amyloid (13-27)
  • HY-14537R
    Latrepirdine dihydrochloride (Standard)
    		Inhibitor
    Latrepirdine (dihydrochloride) (Standard) is the analytical standard of Latrepirdine (dihydrochloride). This product is intended for research and analytical applications. Latrepirdine dihydrochloride is a neuroactive compound with antagonist activity at histaminergic, α-adrenergic, and serotonergic receptors. Latrepirdine stimulates amyloid precursor protein (APP) catabolism and amyloid-β (Aβ) secretion.
    Latrepirdine dihydrochloride (Standard)
  • HY-N0148AR
    Rutin hydrate (Standard)
    		Inhibitor
    Rutin (hydrate) (Standard) is the analytical standard of Rutin (hydrate). This product is intended for research and analytical applications. Rutin (Rutoside) hydrate is a flavonoid found in many plants and shows a wide range of biological activities including anti-inflammatory, antidiabetic, antioxidant, neuroprotective, nephroprotective, hepatoprotective and reducing Aβ oligomer activities. Rutin hydrate can cross the blood brain barrier. Rutin hydrate attenuates vancomycin-induced renal tubular cell apoptosis via suppression of apoptosis, mitochondrial dysfunction, and oxidative stress.
    Rutin hydrate (Standard)
  • HY-P4867
    β Amyloid (1-42) (scrambled)
    β Amyloid (1-42) (scrambled) is a negative control of β-Amyloid (1-42), human (HY-P1363A).
    β Amyloid (1-42) (scrambled)
  • HY-B1794AR
    Thiethylperazine dimaleate (Standard)
    		Inhibitor
    Thiethylperazine (dimaleate) (Standard) is the analytical standard of Thiethylperazine (dimaleate). This product is intended for research and analytical applications. Thiethylperazine dimaleate, a phenothiazine derivate, is an orally active and potent dopamine D2-receptor and histamine H1-receptor antagonist. Thiethylperazine dimaleate is also a selective ABCC1activator that reduces amyloid-β (Aβ) load in mice. Thiethylperazine dimaleate has anti-emetic, antipsychotic and antimicrobial effects.
    Thiethylperazine dimaleate (Standard)
  • HY-123228
    CHF5022
    		Inhibitor
    CHF5022 is an inhibitor of Aβ42 secretion (IC50=92 μM). CHF5022 retains a modest activity on Aβ40 at non-cytotoxic concentrations (−22.2±4.8% at 100 μM).
    CHF5022
  • HY-N0022R
    Isoacteoside (Standard)
    		Inhibitor
    Isoacteoside (Standard) is the analytical standard of Isoacteoside. This product is intended for research and analytical applications. Isoacteoside is a natural product that can significantly inhibit the formation of glycation end products. Isoacteoside Standard regulates the AKT/PI3K/m-TOR/NF-κB signaling pathway, induces apoptosis in OVCAR-3 cell. Isoacteoside Standard exhibits antitumor, anti-inflammatory, anti-obesity and neuroprotective activities.
    Isoacteoside (Standard)
  • HY-117259S
    Valiltramiprosate-d6
    		Inhibitor
    Valiltramiprosate-d6 (ALZ-801-d6) is deuterium labeled Valiltramiprosate. ALZ-801 is a potent and orally available small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor, valine-conjugated proagent of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound. ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease.
    Valiltramiprosate-d<sub>6</sub>
  • HY-N9861
    Kayaflavone
    		Inhibitor
    Kayaflavone is an amentoflavone type biflavonoid. Kayaflavone has an inhibitory activity against amyloid-β42 cytotoxicity in PC-12 cells with an EC50 value of 5.29 μΜ. Kayaflavone is promising for research of Alzheimer’s disease.
    Kayaflavone
  • HY-50682R
    Azeliragon (Standard)
    		Inhibitor
    Azeliragon (Standard) is the analytical standard of Azeliragon. This product is intended for research and analytical applications. Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression in patients with mild Alzheimer’s disease (AD). Azeliragon also can cross the blood-brain barrier (BBB).
    Azeliragon (Standard)
  • HY-P1468F
    Biotin-β-amyloid (1-28)
    Biotin-β-amyloid (1-28) (Biotin-amyloid β-protein (1-28)) is abiotinylated β-Amyloid (1-28) (HY-P1468).
    Biotin-β-amyloid (1-28)
  • HY-N2581R
    Phytic acid sodium salt (Standard)
    		Inhibitor
    Phytic acid (sodium salt) (Standard) is the analytical standard of Phytic acid sodium salt (HY-N2581). This product is intended for research and analytical applications. Phytic acid (myo-Inositol; hexakis dihydrogen phosphate; Inositol hexaphosphate) sodium salt is an orally active compound. Phytic acid sodium salt can be derived from the seeds of legumes. Phytic acid sodium salt is a [PO4]3- storage depot and precursor for other inositol phosphates and pyrophosphates. Phytic acid sodium salt attenuates Aβ oligomers and upregulates autophagy protein. Phytic acid sodium salt can be used in cardiovascular disease, metabolic disease, nervous system disease and cancer research.
    Phytic acid sodium salt (Standard)
  • HY-B1588
    Carbenoxolone
    		Inhibitor
    Carbenoxolone, a semi-synthetic derivative of glycyrrhetinic acid, has previously been used for the management of dyspepsia and peptic ulcer because of its anti-inflammatory properties. Carbenoxolone, a general hemichannel and gap junction inhibitor, has the therapeutic potential of carbenoxolone in the treatment of chronic liver disease. Carbenoxolone is a suitable candidate for the inhibition of Aβ42 aggregation and the therapeutic potential of Cbx against AD. Carbenoxolone is small molecule Pannexin1 (Panx1,is an ATP release channel) inhibitor, attenuate Panx1 channel activity through modulation of the first extracellular loop. Carbenoxolone is an 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor. Carbenoxolone has antiviral activity against DENV infection targeting the virus itself.
    Carbenoxolone
  • HY-11054
    TH-237A
    		98.55%
    TH-237A(meso-GS 164) is a neuroprotective agent with good blood-brain barrier permeability.
    TH-237A
  • HY-P5945
    β-Amyloid (1-8, A2V)
    β-Amyloid (1-8, A2V) is amutantion of β-Amyloid (1-8) (HY-P5946).
    β-Amyloid (1-8, A2V)
  • HY-P5946
    β-Amyloid (1-8)
    β-Amyloid (1-8) is aAβ Fragment.
    β-Amyloid (1-8)
Cat. No. Product Name / Synonyms Application Reactivity